Success Metrics

Clinical Success Rate

100.0%

Based on 3 completed trials

Completion Rate

100%(3/3)

Active Trials

1(25%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_1

25%

Ph not_applicable

25%

Ph phase_2

25%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 1Safety & dosage

1(33.3%)

Phase 2Efficacy & side effects

1(33.3%)

N/ANon-phased studies

1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(3)

Detailed Status

Completed3

Recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 2

Trials by Phase

Phase 11 (33.3%)

Phase 21 (33.3%)

N/A1 (33.3%)

Trials by Status

recruiting125%

completed375%

Recent Activity

1 active trials

Showing 4 of 4

completed

Study of Smith-Lemli-Opitz Syndrome

NCT00001721

completednot_applicable

The Effect of Body Mass Index and Total Cholesterol Levels on Histopathological Grading in Breast Cancer Patients

NCT06786598

recruitingphase_2

Cholesterol and Antioxidant Treatment in Patients With Smith-Lemli-Opitz Syndrome (SLOS)

NCT01773278

completedphase_1

Cholesterol in ASD: Characterization and Treatment

NCT00965068

Clinical Trials (4)

Showing 4 of 4 trials

NCT00001721

Study of Smith-Lemli-Opitz Syndrome

Completed

NCT06786598Not Applicable

The Effect of Body Mass Index and Total Cholesterol Levels on Histopathological Grading in Breast Cancer Patients

Completed

NCT01773278Phase 2

Cholesterol and Antioxidant Treatment in Patients With Smith-Lemli-Opitz Syndrome (SLOS)

Recruiting

NCT00965068Phase 1

Cholesterol in ASD: Characterization and Treatment

Completed

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4